We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3349:TSECOSMOS Pharmaceutical Corporation Analysis

Data as of 2026-08-26 - not real-time

₩1,744.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Prestige Biologics Co., Ltd. trades at KRW 1,744.00, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Over a rolling month the price has lost 2.0%. Momentum indicators put RSI at 39.7 (approaching oversold) with MACD reading bearish. The recent range runs from support at KRW 1,667.00 up to resistance at KRW 1,996.00.
On a 1-10 scale the risk profile lands at 7 — elevated. With 30-day volatility of 43.8%, a beta of 0.54 and a maximum drawdown of 54.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 2468.68
  • MACD momentum is negative

Medium Term

1–3 years
Cautious
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 2468.68
  • 30-day volatility of 43.8%

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • 30-day volatility of 43.8%
  • Maximum drawdown of 54.2%
  • Short-term moving averages stacked below long-term ones

Key Metrics & Analysis

Technical Analysis

TrendBearish
RSI39.7
Support₩1,667.00
Resistance₩1,996.00
MA 20₩1,864.30
MA 50₩1,879.88
MA 200₩2,468.69
MACDBearish
VolumeDecreasing
Fear & Greed Index93.84

Valuation

GradeFair
TypeBlend

Risk Assessment

Beta0.54
Volatility43.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.